Search clinical trials for: CXCR4 modified anti-BCMA CAR T cells

Total 1357 results

The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma

B-cell Lymphoma

China
The Second Affiliated Hospital of Henan University...
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng... and other collaborators

Unknown

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Multiple Myeloma

China
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Multiple Myeloma

United States, Canada
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma

China
Antonio Pérez Martínez

Recruiting

A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma (CAR4SAR)

Advanced Sarcoma

Spain
Autolus Limited

Enrolling by invitation

Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified

Multiple Myeloma | DLBCL | T Cell Lymphoma | Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy | ALL, Adult and Pediatric

United Kingdom
National Cancer Institute (NCI)

Completed

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

Myeloma-Multiple | Myeloma, Plasma-Cell

United States
Ruijin Hospital
UTC Therapeutics Inc.

Recruiting

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto)

Refractory Malignant Solid Neoplasm

China
China Meitan General Hospital
Marino Biotechnology Co., Ltd.

Unknown

Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

Mesothelin Positive Tumors

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Institute of Hematology & Blood Diseases Hospital...
Juventas Cell Therapy Ltd.

Recruiting

CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Autoimmune Hemolytic Anemia | Autologous CD19 CAR-T | Failure of Three or More Lines of Therapy

China
Celyad Oncology SA

Terminated

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer (LINK)

Colon Cancer Liver Metastasis

Belgium
Celyad Oncology SA

Unknown

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases (SHRINK)

Colon Cancer Liver Metastasis

Belgium
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Non-hodgkin's Lymphoma

China
University of Erlangen-Nürnberg Medical School

Recruiting

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease (CASTLE)

Systemic Lupus Erythematosus | Systemic Sclerosis | Dermatomyositis | Polymyositis

Germany
Roger Williams Medical Center

Completed

CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells (HITM)

Liver Metastases

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Guangzhou 8th People's Hospital
Sun Yat-sen University

Completed

Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir

HIV/AIDS

China
Sinobioway Cell Therapy Co., Ltd.
Jiangsu Cancer Institute & Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma (EECPL)

Lymphoma

China
Roger Williams Medical Center

Suspended

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Prostate Cancer

United States
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

Acute Lymphoblastic Leukemia in Remission

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
Fundacion Clinic per a la Recerca Biomédica

Not yet recruiting

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma (CARTD-BG-1)

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

Spain
iCell Gene Therapeutics
The General Hospital of Western Theater Command; Peking University Shenzhen... and other collaborators

Recruiting

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Active, not recruiting

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

POMES Syndrome | Relapsed and Refractory POMES Syndrome

China
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Not yet recruiting

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Hepatocellular Carcinoma | Liposarcoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Malignant Rhabdoid Tumor | Yolk Sac Tumor | Embryonal Sarcoma of Liver

United States
Sichuan University

Recruiting

Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Malignant Ascites | Malignant Peritoneal Effusion | Serous Cavity Metastatises

China
Sichuan University

Recruiting

Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis

Pleural Effusion, Malignant | Peritoneal Carcinoma Metastatic

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Solid Tumor | Liver Cancer

China
Roger Williams Medical Center
Sirtex Medical

Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases (HITM-SIR)

Liver Metastases

United States
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; 920th Hospital of Joint Logistics Support... and other collaborators

Not yet recruiting

Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Lymphoma, Non-Hodgkin

China
Sichuan University

Not yet recruiting

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
Chinese PLA General Hospital

Unknown

Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Chongqing University... and other collaborators

Unknown

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

B Cell Leukemia | Relapsed Adult ALL

China
Shenzhen University General Hospital

Unknown

Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia (CAR-T)

Refractory B Acute Lymphoblastic Leukemia | Relapse | B ALL | Dual-target CAR-T Cells

China
Second Affiliated Hospital of Guangzhou Medical...
Fapon Biotherapy Inc.

Recruiting

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Pancreas Cancer | Solid Tumor, Adult | CAR-T Cell Therapy | Mesothelin

China
Janssen Research & Development, LLC

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Multiple Myeloma

United States, Belgium, China, Israel, Netherlands, Spain, Japan
The First Affiliated Hospital of Soochow University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

Acute Myeloid Leukemia | Mixed Phenotype Acute Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
Peng Liu
Shanghai East Hospital; Hrain Biotechnology

Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Peking University
Marino Biotechnology Co., Ltd.

Unknown

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

B-cell Lymphoma

China
Groupe Hospitalier Pitie-Salpetriere

Completed

Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events (CARTABLE)

Cancer | Adverse Drug Reactions

France
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
YuLi

Unknown

Dual Target CAR-T Cells in B-cell Lymphoma (CAR-T)

Lymphoma, B-Cell | Refractory Lymphoma | Relapse/Recurrence | Dual-target CAR-T Cells

China
Shenzhen BinDeBio Ltd.
Henan Provincial People's Hospital

Recruiting

Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies

Glioma | Gastric Cancer | Hepatoma | Esophagus Cancer

China
University of Pennsylvania

Completed

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy (MazF)

HIV

United States
National Cancer Institute (NCI)

Completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-cell | Lymphoma, Hodgkins | Lymphoma, Non-hodgkins

United States

Search clinical trials for: CXCR4 modified anti-BCMA CAR T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations